Bromantane (Ladasten)
Adamantane Actoprotector | Dopamine Synthesis Enhancer
Bromantane (Ladasten) is a unique adamantane derivative and actoprotector developed in the 1980s at the Zakusov State Institute of Pharmacology in Russia, originally field-tested by the Soviet military in Afghanistan for heat stress and marching fatigue. Unlike traditional stimulants that work through receptor agonism or reuptake inhibition, bromantane enhances dopamine and serotonin synthesis by upregulating the gene expression of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC) — the rate-limiting enzymes in catecholamine production. It also strengthens GABAergic signaling by reducing GABA transporter expression, producing anxiolytic effects without sedation. Approved in Russia in 1997 for the treatment of asthenic disorders (neurasthenia), it uniquely combines stimulant and anxiolytic properties without tolerance, dependence, or withdrawal. A landmark 728-patient clinical trial demonstrated a 76% response rate with only 3% side effects.
Daily dose
50-100mg
Frequency
Once daily
Cycle length
2-4 weeks on, 1-2 weeks off
Storage
Room temperature
Key benefits
Unique dual stimulant-anxiolytic action via dopamine/serotonin synthesis enzyme upregulation. No tolerance, dependence, or withdrawal. 76% clinical response rate in 728-patient trial. Enhanced physical and cognitive performance under stress. Immunostimulatory effects.
How it works
Upregulates gene expression of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC) in the substantia nigra, VTA, and hypothalamus, increasing endogenous dopamine and serotonin synthesis 2-2.5 fold. Also reduces GABA transporter expression for anxiolytic effects. This genomic mechanism provides sustained neurotransmitter enhancement without receptor desensitization.
Dosage protocols
Goal
Standard nootropic/anti-asthenia
Dose
50mg · Once daily
Route
Oral
Goal
Full therapeutic dose
Dose
100mg · Once daily
Route
Oral
Goal
Conservative start
Dose
25mg · Once daily
Route
Oral
Research indications
cognitive
anxiolytic
physical
Administration
Interactions
Safety notes
Exceptional safety profile: LD50 of 9000 mg/kg (rat), only 3% side effects in 728-patient trial
No tolerance, dependence, or withdrawal documented
Not FDA approved — investigational/research compound
Avoid combining with MAOIs (theoretical risk based on mechanism)
Monitor if combining with SSRIs (theoretical metabolic interaction concern)
Highly lipophilic — accumulates in adipose tissue
Research studies
Multicenter Asthenia Clinical Trial (2009)
728 patients | 50-100mg daily | 28 days | Multicenter open-label | CGI-S and CGI-I assessment
Landmark Russian multicenter trial demonstrating 76% response rate on CGI-S (Clinical Global Impression - Severity) and 90.8% improvement on CGI-I (Clinical Global Impression - Improvement). Only 3% experienced side effects with 0.8% discontinuation rate, establishing an exceptional safety-to-efficacy ratio.
View study →Tyrosine Hydroxylase Gene Expression Study (2007)
Animal | Rat hypothalamus | 10-50mg/kg | 7 days | RT-PCR analysis of TH and AADC mRNA
Demonstrated that bromantane increases tyrosine hydroxylase (TH) mRNA expression 2-2.5 fold in the rat hypothalamus and striatum, confirming its unique mechanism of enhancing dopamine synthesis at the gene expression level rather than through receptor modulation.
View study →Pharmacokinetic Profile Study
Human | 100mg single dose | Plasma analysis | Gender-stratified PK parameters
Established key pharmacokinetic parameters: 42% oral bioavailability, half-life of 11.21 hours, Tmax of 2.75 hours in females and 4 hours in males. Primary metabolite 6β-hydroxybromantane detected in urine up to 2 weeks post-administration due to lipophilic tissue deposition.
View study →Anxiolytic Properties Without Sedation
Animal | Rat and mouse models | Elevated plus maze and open field tests | Multiple inbred strains
Demonstrated significant anxiolytic effects in validated anxiety models (elevated plus maze, open field) across multiple inbred strains differing in stress responses, without the sedation, muscle relaxation, or cognitive impairment typical of benzodiazepines. Effects were mediated through dopaminergic and serotonergic enhancement.
View study →Immunostimulatory Activity Study
Animal | Mouse | Immune function assays | Acute and chronic dosing
Revealed bromantane's immunostimulatory properties including enhanced phagocytic activity and T-cell function. These effects were attributed to its ability to modulate the hypothalamic-pituitary-adrenal axis and enhance cellular immune responses.
View study →Physical Performance Enhancement (Actoprotector) Study
Human | Athletes | Physical endurance testing | Heat and physical stress conditions
Demonstrated significant improvements in physical work capacity under conditions of heat stress and exhaustive exercise, establishing bromantane as a premier actoprotector. Performance benefits occurred without the cardiovascular strain typical of sympathomimetic stimulants.
View study →